Breast

Elsevier

Journal websitePeer review: Other
Evaluation status available after sign-in

About the journal

Breast is an open-access journal published by Elsevier in United Kingdom, publishing in english. It is listed in DOAJ and MEDLINE according to the sources read. Declared publication charge: 3,770 USD. Declared review time at DOAJ: 15 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
Elsevier
ISSN
1532-3080
Country
United Kingdom
Languages
english
Access
Open access
Declared publication charge
3,770 USD
Articles in DOAJ
1827
Declared review time
15 weeks
Declared peer-review model
other

Index listings

  • DOAJ · 2020-09-25
  • MEDLINE · 2003-01-01
Indexing
DOAJ · MEDLINE
APC
3,770 USD
Declared review time (DOAJ)
15 weeks
Actual review time (measured)
116 days received→accepted — computed from PubMed (n=98)
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Articles in DOAJ

1827

Most recent article

last month

Average review time (journal-declared via DOAJ)

15weeks

Works in OpenAlex

10532

Last recorded publication year

2026

Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

128

i10-index

2709

From OpenAlex open data (CC0).

Editorial & policy12
Last DOAJ review date
2026-04-27
Added to DOAJ
2020-09-25
Declared plagiarism screening
Declared
Other fees beyond APC
No
Declared digital preservation
CLOCKSSPMCPortico
Observed digital preservation (Keepers registry)— snapshot 2026-10-05
CLOCKSSPortico
Editorial board
Official page ↗
Norwegian register (HK-dir)— 2026
Level 1 — approved scholarly channel
Open references deposited at Crossref
49%
ORCID iDs in current deposits
42%
Deposits licence metadata at Crossref
✓
APC waiver policy
View policy
Peer-review policy
View policy
Identity & continuity2
Source type
journal
NLM unique ID (PubMed)
9213011
Classification2

Subjects (DOAJ)

Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens

LCC codes

RC254-282

Subject areas

  • Breast Cancer Treatment Studies
  • Breast Cancer Treatment Studies
  • Breast Cancer Treatment Studies
  • Breast Lesions and Carcinomas
  • Breast Lesions and Carcinomas
  • Breast Lesions and Carcinomas
  • BRCA gene mutations in cancer
  • Cancer Treatment and Pharmacology
Show all subjects (75)
  • Cancer Treatment and Pharmacology
  • Global Cancer Incidence and Screening
  • HER2/EGFR in Cancer Research
  • HER2/EGFR in Cancer Research
  • Global Cancer Incidence and Screening
  • Advanced Breast Cancer Therapies
  • Advanced Breast Cancer Therapies
  • Breast Implant and Reconstruction
  • Breast Implant and Reconstruction
  • Breast Implant and Reconstruction
  • Cancer survivorship and care
  • Women's cancer prevention and management
  • Global Cancer Incidence and Screening
  • HER2/EGFR in Cancer Research
  • MRI in cancer diagnosis
  • Advanced Breast Cancer Therapies
  • Estrogen and related hormone effects
  • Estrogen and related hormone effects
  • BRCA gene mutations in cancer
  • BRCA gene mutations in cancer
  • Cancer Risks and Factors
  • Cancer Risks and Factors
  • Estrogen and related hormone effects
  • Digital Radiography and Breast Imaging
  • Gastric Cancer Management and Outcomes
  • Cancer Treatment and Pharmacology
  • Cancer Risks and Factors
  • Cancer survivorship and care
  • Cancer survivorship and care
  • Endometrial and Cervical Cancer Treatments
  • AI in cancer detection
  • Cancer Genomics and Diagnostics
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer
  • Economic and Financial Impacts of Cancer
  • Cancer and Skin Lesions
  • Cancer and Skin Lesions
  • Cancer Diagnosis and Treatment
  • Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Reconstructive Surgery and Microvascular Techniques
  • Reconstructive Surgery and Microvascular Techniques
  • Medical Imaging Techniques and Applications
  • Medical Imaging Techniques and Applications
  • Radiomics and Machine Learning in Medical Imaging
  • Radiomics and Machine Learning in Medical Imaging
  • Advances in Oncology and Radiotherapy
  • Advances in Oncology and Radiotherapy
  • Patient-Provider Communication in Healthcare
  • Metastasis and carcinoma case studies
  • Male Breast Health Studies
  • Male Breast Health Studies
  • Cancer Cells and Metastasis
  • Cancer Cells and Metastasis
  • Cancer Cells and Metastasis
  • Health Systems, Economic Evaluations, Quality of Life
  • Health Systems, Economic Evaluations, Quality of Life
  • AI in cancer detection
  • AI in cancer detection
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Treatments and Mutations
  • Male Breast Health Studies
  • Bone health and treatments
  • Bone health and treatments
  • Menopause: Health Impacts and Treatments
  • Bone health and treatments
  • Multiple and Secondary Primary Cancers

Keywords (DOAJ)

  • breast cancer
  • translational and clinical research
  • prevention
  • diagnosis
  • treatment
  • breast cancer surgery

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: